Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records. by McDonald, Helen I et al.
McDonald, HI; Thomas, SL; Millett, ERC; Quint, J; Nitsch, D (2017)
Do influenza and pneumococcal vaccines prevent community-acquired
respiratory infections among older people with diabetes and does
this vary by chronic kidney disease? A cohort study using electronic
health records. BMJ open diabetes research & care, 5 (1). e000332.
ISSN 2052-4897 DOI: https://doi.org/10.1136/bmjdrc-2016-000332
Downloaded from: http://researchonline.lshtm.ac.uk/4266995/
DOI: 10.1136/bmjdrc-2016-000332
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Do inﬂuenza and pneumococcal
vaccines prevent community-acquired
respiratory infections among older
people with diabetes and does this vary
by chronic kidney disease? A cohort
study using electronic health records
Helen I McDonald,1 Sara L Thomas,2 Elizabeth R C Millett,2 Jennifer Quint,3
Dorothea Nitsch1
To cite: McDonald HI,
Thomas SL, Millett ERC,
et al. Do influenza and
pneumococcal vaccines
prevent community-acquired
respiratory infections among
older people with diabetes
and does this vary by chronic
kidney disease? A cohort
study using electronic health
records. BMJ Open Diabetes
Research and Care 2017;5:
e000332. doi:10.1136/
bmjdrc-2016-000332
A first draft of the manuscript
was included in a PhD thesis
by HIMD at the London
School of Hygiene and
Tropical Medicine in 2015,
but not otherwise published
previously in whole or part.
Received 28 September 2016
Revised 12 January 2017
Accepted 24 January 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Helen I McDonald; helen.
isabel.mcdonald@gmail.com
ABSTRACT
Objective: We aimed to estimate the effectiveness of
influenza and 23-valent pneumococcal polysaccharide
vaccination on reducing the burden of
community-acquired lower respiratory tract infection
(LRTI) among older people with diabetes, and
whether this varied by chronic kidney disease (CKD)
status.
Research design and methods: We used linked
UK electronic health records for a retrospective
cohort study of 190 492 patients ≥65 years with
diabetes mellitus and no history of renal replacement
therapy, 1997–2011. We included community-
acquired LRTIs managed in primary or secondary
care. Infection incidence rate ratios were estimated
using the Poisson regression. Pneumococcal vaccine
effectiveness (VE) was calculated as (1−effect
measure). To estimate influenza VE, a ratio-of-ratios
analysis (winter effectiveness/summer effectiveness)
was used to address confounding by indication.
Final VE estimates were stratified according to
estimated glomerular filtration rate and proteinuria
status.
Results: Neither influenza nor pneumococcal
vaccine uptake varied according to CKD status.
Pneumococcal VE was 22% (95% CI 11% to 31%)
against community-acquired pneumonia for the first
year after vaccination, but was negligible after
5 years. In the ratio-of-ratios analysis, current
influenza vaccination had 7% effectiveness for
preventing community-acquired LRTI (95% CI 3 to
12). Pneumococcal VE was lower among patients
with a history of proteinuria than among patients
without proteinuria (p=0.04), but otherwise this
study did not identify variation in pneumococcal or
influenza VE by markers of CKD.
Conclusions: The public health benefits of influenza
vaccine may be modest among older people with
diabetes. Pneumococcal vaccination protection
against community-acquired pneumonia declines
swiftly: alternative vaccination schedules should be
investigated.
INTRODUCTION
Hospital admissions for pneumonia are rising
rapidly in the UK, most steeply among older
people.1 Older people with diabetes have a
Significance of this study
What is already known about this subject?
▪ There is a large and growing burden of
community-acquired lower respiratory tract infec-
tion and pneumonia among older people with
diabetes, much of which can be directly or indir-
ectly attributed to two vaccine-preventable patho-
gens: pneumococcus and influenza.
What are the new findings?
▪ We observed only a modest effectiveness of influ-
enza vaccine against community-acquired lower
respiratory tract infection (after adjustment for con-
founding by indication), while the effectiveness of
pneumococcal vaccine against pneumonia waned
over time. Our results suggested that pneumococ-
cal vaccine effectiveness may be lower among
patients with proteinuria but did not otherwise vary
according to markers of chronic kidney disease.
How might these results change the focus
of research or clinical practice?
▪ More effective immunization strategies and vac-
cination schedules may be needed for older
people with diabetes.
▪ The low influenza vaccine effectiveness (VE) we
observed against community-acquired lower
respiratory tract infection, when contrasted with
the large burden of infection directly and indir-
ectly attributed to influenza, suggests scope for
improved influenza immunization among this
population, for example, with adjuvants.
▪ The suggestion of reduced pneumococcal VE
among patients with proteinuria needs confirm-
ation in a repeat study.
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particularly high burden of lower respiratory tract infec-
tion (LRTI), including pneumonia.2
Directly or indirectly, Streptococcus pneumoniae
(‘pneumococcus’) and seasonal inﬂuenza viruses are
responsible for a large burden of community-acquired
pneumonia. The most common cause of community-
acquired pneumonia is S. pneumoniae.3 Up to a third of
community-acquired pneumonia may be inﬂuenza-
related, due to bacterial coinfection or secondary bacter-
ial pneumonia.4 Vaccination is available against both
these pathogens, and recommended in the UK for every-
one aged ≥65 years.5 However, the extent to which these
vaccines protect against pneumonia among older people
remains unclear for both vaccines.
The effectiveness of 23-valent pneumococcal polysac-
charide vaccination against all-cause pneumonia among
older people has been questioned, although meta-analyses
have been hampered by between-study heterogeneity.6 7
Waning immunity among vaccinated participants has been
suggested as a possible cause, but few estimates are
available of pneumococcal vaccine effectiveness (VE)
according to time since vaccination.8
Traditional observational studies of inﬂuenza VE
among older people may have overestimated inﬂuenza
VE due to uncontrolled confounding by indication, in
which the patient’s functional status affects vaccine
uptake.8–12 Observational studies which used strategies to
control confounding by indication (such as a ‘ratio-of-ratios’
analysis in which the excess inﬂuenza VE during winter
compared with summer is calculated) have suggested a null
or modest inﬂuenza VE against community-acquired pneu-
monia among older people.9 13–15
Older people with diabetes have a high prevalence of
chronic kidney disease (CKD).16 Even at early stages,
patients with CKD have increased incidence of LRTI
and pneumonia.16–18 Patients with CKD have a generally
reduced response to vaccines, and a faster decline in
antibody levels following vaccination.19 Among patients
receiving hemodialysis, a ratio-of-ratios analysis of inﬂu-
enza VE found no evidence of any protection against
inﬂuenza-like-illness, inﬂuenza/pneumonia hospitaliza-
tion, or mortality.20 Inﬂuenza VE at earlier stages of
CKD is unclear, and still less is known about pneumo-
coccal VE among patients with CKD.19 21
We aimed to describe the extent to which the burden
of community-acquired LRTI and pneumonia among
older people with diabetes may be preventable with
pneumococcal and inﬂuenza vaccination, and whether
this varied according to CKD status. We conducted a
retrospective cohort study using linked primary and
secondary care electronic health record data to calculate
the VE of pneumococcal vaccine against all community-
acquired pneumonia. Since inﬂuenza vaccine may
potentially reduce the incidence of inﬂuenza infection
and secondary pneumonia, we calculated the inﬂuenza
VE to prevent all community-acquired LRTI (considered
as a broad category of all ‘chest infections’, including
inﬂuenza infections, and possible secondary infections
such as bronchitis and pneumonia), using a
ratio-of-ratios analysis to address confounding by
indication.
RESEARCH DESIGN AND METHODS
Data sources
We analyzed data from the Clinical Practice Research
Datalink (CPRD), a database of anonymized primary
care medical records. Data were extracted in May 2011,
and contained records for 12.8 million patients at 627
practices across the UK.22 Records include patient demo-
graphics, health behaviors, test results, diagnoses, and
prescriptions. Diagnoses are recorded using Read codes,
and have generally been found to have good positive
predictive value in validations.23 The CPRD population
is similar to the general UK population in terms of age
and sex.24 25
Linked data are available for patients in England,
subject to practice-level consent. This study used linked
data on all hospital inpatient admissions to NHS hospi-
tals in England from Hospital Episodes Statistics (HES),
and socioeconomic status from the Ofﬁce for National
Statistics (ONS).
Study population
The study population comprised all patients in CPRD
with diabetes mellitus, aged ≥65 years, with no history of
renal replacement therapy, who had at least one valid
serum creatinine result recorded in primary care.
Diabetes was identiﬁed by diagnostic Read codes. For less
deﬁnitive Read codes, we required conﬁrmation with an
antidiabetic medication prescription, as described in
detail previously.2
Patients met eligibility criteria at the latest time-point
of: diabetes diagnosis, 65th birthday, 1 year after practice
registration, their general practice fulﬁlling CPRD
quality control standards, or 1 April 1997. Their study
entry date was their ﬁrst valid serum creatinine result
after the eligibility criteria were met. Patients left the
study at the ﬁrst time-point of: death, leaving the prac-
tice, last data collection from the practice, renal replace-
ment therapy (dialysis or renal transplant), or 31 March
2011. Patients with a diagnosis of HIV or hyposplenia
(including celiac disease or sickle cell disease) at any
point in their medical record were excluded from the
study.
Definition of infections
LRTI was deﬁned as a broad category of all infections of
the lower respiratory tract, including inﬂuenza infec-
tions, bronchitis, and pneumonia.
A clinical diagnosis of infection was identiﬁed by a
diagnostic Read code in primary care records, or a diag-
nostic International Classiﬁcation of Disease 10
(ICD-10) code as the primary cause of hospital admis-
sion in secondary care records. To avoid overestimation
from repeat attendances for the same infection,
2 BMJ Open Diabetes Research and Care 2017;5:e000332. doi:10.1136/bmjdrc-2016-000332
Epidemiology/health services research
 o
n
 4 M
ay 2018 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2016-000332 on 3 April 2017. Downloaded from 
diagnostic codes recorded within 28 days of one another
were attributed to a single episode of infection. The ﬁrst
consultation for infection was treated as the date of
infection onset, and the infection had duration until
28 days after the latest of the last diagnostic code or hos-
pital discharge. All infections with onset date during a
HES hospitalization spell, or within 14 days following
hospital discharge, or which included a code for post-
operative infection, were designated hospital-acquired,
and excluded. These methods have been described in
detail previously.26
Time at risk
Patients were not at risk of incident community-acquired
infection during ongoing infection (community-
acquired or hospital-acquired), during any hospitaliza-
tion, or within 14 days following hospital discharge.
These time periods were removed from time at risk. As
pneumonia was a subset of LRTI, a patient could be at
risk of pneumonia during an ongoing LRTI.
Assignment of vaccination status
Vaccination status was identiﬁed from primary care
records using Read codes, prescription data, and immun-
ization record forms.
For pneumococcal vaccination, any of these records
could deﬁne a ﬁrst vaccination, and any subsequent pre-
scription could identify a booster vaccination.
Time-updated pneumococcal vaccination status was clas-
siﬁed according to time since the latest pneumococcal
vaccination (<1, 1–5, ≥5 years, never vaccinated).
Time-updated inﬂuenza vaccination status was
assigned within vaccination years (1 September to 31
August). Within each vaccination year, inﬂuenza vaccin-
ation status was current from the ﬁrst vaccination record
to the subsequent 31 August. Patients without a current
vaccination who had received an inﬂuenza vaccination
within any of the previous ﬁve vaccination years were clas-
siﬁed as having ‘residual’ inﬂuenza vaccination status,
and other patients were categorized as unvaccinated.
Definition of CKD
We studied two markers of CKD: estimated glomerular
ﬁltration rate (eGFR) and proteinuria. Estimated GFR
was calculated from serum creatinine test results in
primary care, using the CKD-EPI equation, including
adjustment for black ethnicity.27 Estimated GFR status
was time-updated using a last-carried-forward method,
with eGFR status assigned according to the most recent
creatinine result.17
A history of proteinuria was established from a Read
code for persistent proteinuria or proteinuric disease, or
a positive test result which did not coincide with a
urinary tract infection diagnosis.
Definitions for covariates
Age was categorized in 5-year bands up to a ﬁnal cat-
egory of ≥85 years. Socioeconomic status was assigned at
a practice level, using 2007 ONS estimates of the Index
of Multiple Deprivation, a composite area-level marker
of deprivation.28 Smoking status was identiﬁed as
current, ex-smoker, or non-smoker from HES or CPRD
records. Comorbidities were identiﬁed from diagnostic
Read codes in CPRD and were modeled as separate vari-
ables which were: ischemic heart disease, congestive
cardiac failure, hypertension, cerebrovascular disease,
other dementia, chronic lung disease (which included
chronic obstructive pulmonary disease but not asthma),
and chronic liver disease. Baseline HbA1C was deﬁned
by the most recent HbA1C test result in CPRD prior to
(or on) the study entry date. Baseline medication history
was identiﬁed from CPRD prescription records.
Data analysis
Analysis was conducted separately for pneumococcal VE
against pneumonia and for inﬂuenza VE against LRTI.
We excluded patients with missing smoking status. For
comorbidities and proteinuria status, the absence of a
positive record was treated as the absence of disease.
The absence of a recorded HbA1C test result was
included as indicating a relevant category of control.
Incidence rates and rate ratios were calculated for
each infection using the Poisson regression with lexis
expansions for age, and a random effects model to
adjust for multiple infection episodes. We adjusted
models for prespeciﬁed a priori confounders of the asso-
ciation between vaccination status and respiratory infec-
tion, and/or the relationship between CKD and
respiratory infection. These were: age, sex, socio-
economic status at practice level, residential or nursing
home care, baseline smoking status, time-updated
comorbidities, steroid use in the 3 months prior to study
entry, HbA1C and diabetic medication history at base-
line, and date prior to or post 1 April 2004 (when
Quality Outcomes Framework guidelines introduced
ﬁnancial incentives for recording CKD status among
people with diabetes in primary care which may have
improved ascertainment of CKD in primary care).29 No
direct biological effect of ethnicity on VE was expected
and so we did not adjust for this directly: instead, we
adjusted for factors which may mediate any indirect con-
founding effect of ethnicity, such as CKD and other
comorbidities and health behaviors.
For pneumococcal vaccine, VE was calculated as
(1−effect estimate). To explore waning of immunity, we
described pneumococcal VE according to time since
vaccination.
To control for confounding by indication in inﬂuenza
vaccination, we estimated the ratio of inﬂuenza VE in
summer to inﬂuenza VE in winter in a ‘ratio-of-ratios’
analysis by including an interaction term between inﬂu-
enza vaccination status and season, and reporting the
antilog of the β coefﬁcient for the interaction term.20
Winter was deﬁned as 1 September to 31 March, to
capture excess winter inﬂuenza-like-illness.30
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Final estimates of VE were stratiﬁed by time-updated
eGFR and history of proteinuria, as markers of CKD.
Stata V.13.1 was used for data analyses. All code lists
are available on request.
Sensitivity analyses
Twenty-three-valent pneumococcal polysaccharide vac-
cination has been recommended for patients with CKD
in the UK since 1992, but in 2003, the recommendation
was extended to everyone aged ≥65 years.5 As a sensitiv-
ity analysis, we estimated pneumococcal VE separately
for the periods before and after 31 March 2003 (to
avoid separating the 2002–2003 winter season) to check
for bias from secular changes in vaccine uptake.
The match of inﬂuenza vaccine strain to circulating
inﬂuenza varies each year, which affects VE.20 As a sensi-
tivity analysis, we estimated inﬂuenza VE separately for
each winter. A further sensitivity analysis deﬁned the
start of the inﬂuenza season as the ﬁrst week after 1
September in which weekly inﬂuenza-like illness inci-
dence in primary care exceeded 30/100 000 people,
limited to the years 2004–2011 due to data availability.31
We also conducted a sensitivity analysis of inﬂuenza
VE excluding patients with chronic lung disease or con-
gestive heart failure, as the relationship of inﬂuenza to
LRTI etiology for these patients may differ from that
among the general population.
For both vaccines, we conducted a sensitivity analysis
limited to patients with white ethnicity.
Ethics
The study was approved by the Independent Scientiﬁc
Advisory Group of the CPRD (ISAC reference 11_033A)
and the London School of Hygiene and Tropical
Medicine Ethics Committee (LSHTM reference 6116).
RESULTS
Of 193 470 eligible patients, 1049 patients (0.5%) with a
diagnosis of HIV or hyposplenia, 1764 (0.9%) patients
with no smoking status available, and 165 (<0.1%)
patients who had a record of pneumococcal vaccine
administration with a missing date were excluded from
both analyses (ﬁgure 1). For pneumococcal and inﬂu-
enza vaccinations, unvaccinated patients had a lower
recorded prevalence of ischemic heart disease and
chronic lung disease than vaccinated patients.
Unvaccinated patients may have had poorer diabetic
control than vaccinated patients: a higher proportion
had poor or unrecorded HbA1C status, and a lower pro-
portion had a history of oral antidiabetic medication
and insulin prescription than vaccinated patients. The
prevalence of CKD was similar for vaccinated and unvac-
cinated patients, although unvaccinated patients had a
slightly lower prevalence of a recorded history of pro-
teinuria (table 1).
Pneumococcal vaccine
A total of 190 492 patients contributed 811 498 person-
years to the pneumococcal vaccine analysis, during
which there were 7805 community-acquired pneumonia
episodes among 7036 people. At study entry, 58.3% of
patients (111 016/190 492) were vaccinated against
pneumococcal disease (table 1). Baseline pneumococcal
vaccination increased among patients who entered the
study after 2003–2004, and did not differ according to
eGFR at baseline (see online supplementary figure
S1A).
Crude rates of pneumonia were lowest among patients
within a year of pneumococcal vaccine. The adjusted
effectiveness of pneumococcal vaccine for preventing
pneumonia was 22% (95% CI 11% to 31%) within the
ﬁrst year after vaccination, and fell with increasing time
since vaccination. Pneumonia incidence among patients
vaccinated more than 5 years previously was similar to
that among patients with no record of vaccination (inci-
dence rate ratio, IRR 1.03: 95% CI 0.95 to 1.11). There
was the suggestion of a trend of decreased pneumococ-
cal VE among patients with reduced eGFR, but this was
not statistically signiﬁcant. There was a greater protective
effect of pneumococcal vaccine among patients without
Figure 1 Flow chart of study inclusion. LRTI, lower
respiratory tract infection.
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Table 1 Baseline description of study population
Pneumococcal vaccine status at
baseline
n=190 492
Influenza vaccine status at baseline
n=190 459
Never vaccinated
n=79 476
Vaccinated
n=111 016
Unvaccinated*
n=32 552
Currently vaccinated
n=124 130
Residual
1–5 years
n=33 777
Age (years) 71 (66–77) 72 (66–78) 71 (66–77) 72 (66–78) 71 (66–78)
Median (IQR) n (%) n (%) n (%) n (%) n (%)
Female 40 308 (50.7) 53 146 (47.9) 16 603 (51.0) 60 019 (48.4) 16 813 (49.8)
Socioeconomic status†
1 (least deprived) 13 701 (17.2) 19 912 (17.9) 5618 (17.3) 22 181 (17.9) 5809 (17.2)
2 14 666 (18.5) 19 591 (17.7) 5799 (17.8) 22 394 (18.0) 6058 (17.9)
3 16 156 (20.3) 23 329 (21.0) 6567 (20.2) 25 957 (20.9) 6956 (20.6)
4 17 758 (22.3) 25 481 (23.0) 7312 (22.5) 28 128 (22.7) 7789 (23.1)
5 (most deprived) 17 195 (21.6) 22 703 (20.5) 7256 (22.3) 25 470 (20.5) 7165 (21.2)
Ethnicity
White 43 357 (54.6) 63 577 (57.3) 17 037 (52.3) 71 268 (57.4) 18 615 (55.1)
South Asian 1515 (1.9) 2353 (2.1) 429 (1.3) 2606 (2.1) 833 (2.5)
Black 923 (1.2) 1167 (1.1) 343 (1.1) 1290 (1.0) 457 (1.4)
Other 636 (0.8) 717 (0.7) 225 (0.7) 860 (0.7) 267 (0.8)
Missing 33 045 (41.6) 43 202 (38.9) 14 518 (44.6) 48 106 (38.8) 13 605 (40.3)
Residential care 1697 (2.1) 3274 (3.0) 436 (1.3) 3516 (2.8) 1016 (3.0)
Smoking status
Non-smoker 38 078 (47.9) 44 713 (40.3) 15 449 (47.5) 52 782 (42.5) 14 543 (43.1)
Current smoker 13 901 (17.5) 16 439 (14.8) 6252 (19.2) 18 327 (14.8) 5756 (17.0)
Ex-smoker 27 497 (34.6) 49 864 (44.9) 10 851 (33.3) 53 021 (42.7) 13 478 (39.9)
Comorbidities
Ischemic heart disease 18 886 (23.8) 34 415 (31.0) 6825 (21.0) 36 761 (29.6) 9713 (28.8)
Congestive cardiac
failure
5935 (7.5) 10 018 (9.0) 2175 (6.7) 10 721 (8.6) 3065 (9.1)
Hypertension 46 626 (58.7) 71 311 (64.2) 18 644 (57.3) 78 252 (63.0) 21 024 (62.2)
Cerebrovascular disease 9714 (12.2) 14 469 (13.0) 3612 (11.1) 16 021 (12.9) 4540 (13.4)
Other dementia 1437 (1.8) 1956 (1.8) 322 (1.0) 2326 (1.9) 729 (2.2)
Chronic lung disease 4016 (5.1) 10 881 (9.8) 1515 (4.7) 10 530 (8.5) 2851 (8.4)
Chronic liver disease 402 (0.5) 734 (0.7) 168 (0.5) 729 (0.6) 240 (0.7)
Steroid use in previous
3 months
2870 (3.6) 5560 (5.0) 1039 (3.2) 5841 (4.7) 1544 (4.6)
Latest HbA1C status
% (mmol/mol)
None recorded 11 202 (14.1) 10 620 (9.6) 4872 (15.0) 13 317 (10.7) 3627 (10.7)
Good <7% (<53) 34 669 (43.6) 53 305 (48.0) 13 621 (41.8) 58 741 (47.3) 15 596 (46.2)
Intermediate
7–10% (53–86)
27 935 (35.2) 41 354 (37.3) 11 389 (35.0) 45 383 (36.6) 12 509 (37.0)
Poor >10% (>86) 5670 (7.1) 5737 (5.2) 2670 (8.2) 6689 (5.4) 2045 (6.1)
Antidiabetes medication history
None 38 755 (48.8) 50 517 (45.5) 16 463 (50.6) 58 195 (46.9) 14 598 (43.2)
Oral 33 623 (42.3) 46 949 (42.3) 13 613 (41.8) 51 914 (41.8) 15 031 (44.5)
Insulin 2889 (3.6) 4136 (3.7) 1024 (3.2) 4687 (3.8) 1314 (3.9)
Oral and insulin 4209 (5.3) 9414 (8.5) 1452 (4.5) 9334 (7.5) 2834 (8.4)
Latest eGFR mL/min/1.73 m2
<30 2098 (2.6) 2986 (2.7) 767 (2.4) 3337 (2.7) 977 (2.9)
30–44 7558 (9.5) 10 607 (9.6) 2932 (9.0) 11 964 (9.6) 3254 (9.6)
45–59 18 678 (23.5) 25 508 (23.0) 7337 (22.5) 29 039 (23.4) 7806 (23.1)
≥60 51 142 (64.4) 71 915 (64.8) 21 516 (66.1) 79 790 (64.3) 21 740 (64.4)
History of proteinuria
No 71 095 (89.5) 94 128 (84.8) 29 231 (89.8) 107 212 (86.4) 28 735 (85.1)
Yes 8381 (10.6) 16 888 (15.2) 3321 (10.2) 16 918 (13.6) 5042 (14.9)
*Not vaccinated within the five previous years.
†Index of multiple deprivation quintile for primary care practice.
eGFR, estimated glomerular filtration rate.
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a history of proteinuria than with a history of proteinuria
(table 2).
A sensitivity analysis of pneumococcal VE stratiﬁed by
date before or after 1 April 2003 suggested that the esti-
mate was not affected by the change in vaccine recom-
mendation in 2003 (see online supplementary table S1).
Influenza vaccine
For the inﬂuenza VE analysis, 190 459 patients contribu-
ted 803 230 person-years to time at risk, during which
there were 114 313 cases of LRTI among 55 685 patients.
At study entry, 65.2% of patients (124 130/190 459) had
received a current vaccination against inﬂuenza (table 1).
Baseline inﬂuenza vaccination status increased slightly
over time, and did not differ by eGFR status (see online
supplementary figure S1B).
Vaccinated patients had a higher crude incidence of
LRTI than unvaccinated patients, in winter and summer.
After adjustment for age, sex, comorbidities, pneumococ-
cal vaccination, and characteristics of diabetes, the winter
incidence rate of LRTI was higher among patients with a
current inﬂuenza vaccine than unvaccinated patients
(IRR 1.19: 95% CI 1.15 to 1.23) and among patients with
residual inﬂuenza vaccination than unvaccinated patients
(IRR 1.23: 95% CI 1.18 to 1.28). Similar or higher,
adjusted IRRs were observed in summer. Using the
ratio-of-ratios analysis, a 7% effectiveness of current inﬂu-
enza vaccine (95% CI 3 to 12) and a 12% effectiveness of
residual inﬂuenza vaccination (95% CI 7 to 17) to
prevent community-acquired LRTI were observed. There
was no evidence to suggest a relationship between VE
and eGFR nor proteinuria (table 3).
Similar results were obtained in sensitivity analyses
of inﬂuenza VE stratiﬁed by year (see online
supplementary table S2), and excluding patients with
chronic lung disease and congestive heart failure (see
online supplementary table S3). Analyses using the
inﬂuenza season dates did not change the results materi-
ally and are not shown.
Sensitivity analysis limited to patients with white ethni-
city did not change the results for either vaccine (results
not shown).
CONCLUSIONS
Inﬂuenza and pneumococcal vaccine uptake was high
among this study population of older people with diabetes
mellitus, and did not vary according to markers of CKD.
Pneumococcal vaccine had 22% (95% CI 11% to 31%)
effectiveness against community-acquired pneumonia
within the ﬁrst year after vaccination. Pneumonia inci-
dence among patients vaccinated more than 5 years previ-
ously was similar to that among patients with no record of
vaccination (IRR 1.03: 95% CI 0.95 to 1.11).
Community-acquired LRTI rates were higher among
patients who received an inﬂuenza vaccination than
among patients who did not, and this relationship
remained after adjustment for age, sex, comorbidities, and
characteristics of diabetes, and was observed in summer
and winter. Traditional analyses would have concluded that
inﬂuenza vaccination is associated with community-
acquired LRTI. However, using the ratio-of-ratios analysis, a
7% effectiveness (95% CI 3% to 12%) of current inﬂuenza
vaccine against community-acquired LRTI was observed.
Table 2 Pneumococcal vaccine effectiveness against pneumonia (n=190 492)
Pneumococcal vaccination status
Never <1 year 1–4 years ≥5 years
Person-time (years) 189 776 51 397 275 841 294 484
Infections (n) 1661 326 2255 3563
Crude pneumonia rate/1000
person-years (95% CI)
9.0 (8.6 to 9.5) 6.6 (5.9 to 7.3) 8.7 (8.3 to 9.1) 13.6 (13.1 to 14.1)
Adjusted* pneumonia rate ratio
(95% CI)
1 (reference) 0.78 (0.69 to 0.89) 0.92 (0.85 to 0.99) 1.03 (0.95 to 1.11)
Vaccine effectiveness* % (95% CI) 0 (reference) 22 (11 to 31) 8 (1 to 15) −3 (−11 to 5)
Vaccine effectiveness* % (95% CI) stratified by eGFR status (mL/min/1.73 m2)
eGFR <30 0 (reference) 6 (−40 to 37) 4 (−22 to 25) 6 (−19 to 26)
eGFR 30–44 0 (reference) 16 (−12 to 37) 1 (−18 to 17) −7 (−27 to 11)
eGFR 45–59 0 (reference) 21 (−1 to 38) 9 (−6 to 21) −1 (−17 to 14)
eGFR ≥60 0 (reference) 26 (11 to 39) 12 (2 to 22) −3 (−15 to 8)
p Value (test for trend)† – 0.25 0.49 0.07
Vaccine effectiveness* % (95% CI) stratified by proteinuria status
No proteinuria 0 (reference) 28 (16 to 38) 13 (5 to 20) 1 (−8 to 10)
Proteinuria 0 (reference) 2 (−25 to 23) −6 (−23 to 9) −19 (−38 to −3)
p Value (interaction)‡ – 0.04 0.03 0.04
*Adjusted for: age, sex, socioeconomic status at practice level, residential care, date post 1 April 2004, smoking status, time-updated
comorbidities (ischemic heart disease, congestive cardiac failure, hypertension, cerebrovascular disease, other dementia, chronic lung
disease, chronic liver disease), time-updated CKD status (eGFR, proteinuria), steroid use in the 3 months prior to study entry, influenza
vaccination status, and HbA1C and diabetic medication history at baseline.
†Wald test for interaction term of pneumococcal vaccine with eGFR.
‡Wald test for interaction term of pneumococcal vaccine with proteinuria.
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Table 3 Lower respiratory tract infection (LRTI) rates and influenza vaccine effectiveness to prevent LRTI by season (n=190 459)
Summer Winter
Influenza vaccination status Influenza vaccination status
>5 years/never Current Residual 1–5 years >5 years/never Current Residual 1–5 years
Person-time (years) 35 233 219 456 74 704 47 352 355 766 70 718
Infections (n) 2363 22 726 8496 5751 62 077 12 900
Crude LRTI rate /1000 py (95% CI) 73.0 (69.5 to 76.5) 111.0 (109.2 to 112.9) 121.3 (118.4 to 124.1) 134.8 (130.3 to 139.2) 187.2 (185.4 to 189.4) 195.5 (191.6 to 199.4)
Crude LRTI rate ratio (95% CI) 1 (ref) 1.52 (1.45 to 1.60) 1.66 (1.58 to 1.75) 1 (ref) 1.38 (1.34 to 1.44) 1.45 (1.40 to 1.51)
Adjusted* LRTI rate ratio (95% CI)
Overall 1 (ref) 1.28 (1.21 to 1.35) 1.39 (1.32 to 1.47) 1 (ref) 1.19 (1.15 to 1.23) 1.23 (1.18 to 1.28)
Stratified by eGFR (mL/min/1.73 m2)
eGFR <30 1 (ref) 1.20 (0.94 to 1.52) 1.29 (1.01 to 1.65) 1 (ref) 1.17 (0.99 to 1.38) 1.20 (1.01 to 1.43)
eGFR 30–44 1 (ref) 1.27 (1.10 to 1.45) 1.31 (1.13 to 1.51) 1 (ref) 1.20 (1.10 to 1.32) 1.20 (1.08 to 1.33)
eGFR 45–59 1 (ref) 1.32 (1.19 to 1.46) 1.40 (1.26 to 1.56) 1 (ref) 1.16 (1.09 to 1.25) 1.20 (1.12 to 1.30)
eGFR ≥ 60 1 (ref) 1.27 (1.19 to 1.37) 1.42 (1.32 to 1.53) 1 (ref) 1.21 (1.15 to 1.27) 1.26 (1.20 to 1.33)
Stratified by proteinuria
No proteinuria 1 (ref) 1.27 (1.20 to 1.35) 1.36 (1.30 to 1.45) 1 (ref) 1.18 (1.13 to 1.23) 1.22 (1.16 to 1.27)
Proteinuria 1 (ref) 1.33 (1.19 to 1.49) 1.50 (1.33 to 1.68) 1 (ref) 1.23 (1.14 to 1.33) 1.27 (1.17 to 1.38)
Ratio of incidence rate ratios* winter/summer (95% CI)
Overall 1 (ref) 0.93 (0.88 to 0.97) 0.88 (0.83 to 0.93)
Stratified by eGFR (mL/min/1.73 m2)
eGFR <30 1 (ref) 0.93 (0.73 to 1.17) 0.90 (0.70 to 1.16)
eGFR 30–44 1 (ref) 0.88 (0.77 to 1.01) 0.86 (0.75 to 1.00)
eGFR 45–59 1 (ref) 0.90 (0.81 to 0.99) 0.87 (0.78 to 0.98)
eGFR ≥ 60 1 (ref) 0.95 (0.89 to 1.02) 0.89 (0.83 to 0.96)
Stratified by proteinuria
No proteinuria 1 (ref) 0.93 (0.88 to 0.99) 0.90 (0.84 to 0.95)
Proteinuria 1 (ref) 0.90 (0.81 to 1.00) 0.83 (0.74 to 0.93)
Vaccine effectiveness (VE)* based on ratio of incidence rate ratios % (95% CI)
Overall 0 (ref) 7 (3 to 12) 12 (7 to 17)
Stratified by eGFR (mL/min/1.73 m2)
eGFR <30 0 (ref) 7 (−17 to 27) 10 (−16 to 30)
eGFR 30–44 0 (ref) 12 (−1 to 23) 14 (0 to 25)
eGFR 45–59 0 (ref) 10 (1 to 19) 13 (2 to 22)
eGFR ≥ 60 0 (ref) 5 (−2 to 11) 11 (4 to 17)
p Value (test for trend)† – 0.31 0.79
Stratified by proteinuria
No proteinuria 0 (ref) 7 (1 to 12) 10 (5 to 16)
Proteinuria 0 (ref) 10 (0 to 19) 17 (7 to 26)
p Value‡ – 0.56 0.26
*Adjusted for: age, sex, socioeconomic status at practice level, residential care, date post 1 April 2004, smoking status, time-updated comorbidities (ischemic heart disease, congestive cardiac
failure, hypertension, cerebrovascular disease, other dementia, chronic lung disease, chronic liver disease), time-updated CKD status (eGFR, proteinuria), steroid use in the 3 months prior to
study entry, pneumococcal vaccination, and HbA1C and diabetic medication history at baseline.
†Wald test for interaction of eGFR with influenza vaccination status and season, with eGFR modeled as a linear variable.
‡Wald test for interaction of proteinuria with influenza vaccine and season.
LRTI, lower respiratory tract infection; py, person-years.
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There was no evidence of a trend in inﬂuenza VE accord-
ing to CKD status. However, there was evidence for a
greater protective effect of pneumococcal vaccine among
patients without a history of proteinuria than patients with
a history of proteinuria.
Previous meta-analyses have found insufﬁcient evi-
dence for a protective effect of pneumococcal vaccine
against all-cause pneumonia among the adult popula-
tion due to heterogeneity.6 7 A subgroup analysis of a
large Spanish cohort study found that only recent
pneumococcal vaccination (<5 years) protected against
hospitalization for all-cause community-acquired pneu-
monia (HR 0.75; 95% CI 0.58 to 0.98) among the
general population aged ≥60 years.8 The authors sug-
gested that the heterogeneity observed in meta-analyses
might be explained by waning immunity among the vac-
cinated population. Our results support this view and
suggest that pneumococcal vaccination appears to be
effective against all-cause community-acquired pneumo-
nia for a year following vaccination among people aged
≥65 years with diabetes, after which time we observed a
decrease in pneumococcal VE to a null effect after
5 years.
Previous cohort studies among older people have pro-
vided evidence of a ‘healthy vaccinee effect’, in which
higher vaccine uptake among healthier patients resulted
in likely overestimation of inﬂuenza VE.9 10 12 32 33
Evidence suggesting a healthy vaccinee effect has also
previously been found among older people with dia-
betes.34–38 In contrast, we observed higher rates of LRTI
among patients who had received an inﬂuenza vaccin-
ation than among unvaccinated patients: our vaccinated
patients appear, on this outcome measure, to be less
healthy than unvaccinated patients. This ﬁnding is intri-
guing. The major difference between our study and
most previous studies of this question is that we have
included community-acquired LRTIs diagnosed and
managed in primary and secondary care. One possible
explanation of the difference is that vaccination may
reﬂect health-seeking behavior in primary care. When
patients develop symptoms of LRTI, patients who attend
primary care for diagnosis and treatment may also be
patients who were more likely to take up the inﬂuenza
vaccine. This ascertainment bias may be less relevant to
studies with hospitalization as an outcome—or could
even be reversed, as vaccinated patients who attended
primary care promptly with LRTI may be less likely to
require hospital admission. An alternative explanation is
that the healthy vaccinee effect observed in studies of
hospitalization for LRTI/pneumonia may reﬂect
residual confounding by ‘frailty’ in which frailer patients
are less likely to take up vaccination and more likely to
be admitted to hospital when they develop infection.
This would be less relevant to diagnosis of LRTI in
primary care, and so our outcome may be less vulner-
able to residual confounding by indication.
Our ‘ratio-of-ratios’ estimate suggested 7% VE of
current inﬂuenza vaccination against LRTI among older
people with diabetes (95% CI 3 to 12). Previous studies
using similar strategies among the general population of
older people have found no evidence of inﬂuenza VE
against community-acquired pneumonia (VE 8%: 95%
CI −10% to 23%), and evidence of a modest protection
against inﬂuenza-related excess hospitalization with
pneumonia/inﬂuenza (VE 19%: 95% CI 4% to
31%).14 15 Our estimate is consistent with both these
estimates, and the difference may be due to the higher
precision available for the present study due to the large
cohort size.
Our results suggested that pneumococcal VE may be
reduced among patients with a history of proteinuria.
We did not ﬁnd any evidence of altered inﬂuenza VE
among patients with CKD, but this may be due to
limited power for the stratiﬁed ratio-of-ratios analysis. To
the best of our knowledge, neither pneumococcal VE
against pneumonia nor inﬂuenza VE against LRTI using
methods to control for confounding by indication has
been studied among patients with CKD who are not
receiving dialysis. Studies of patients receiving dialysis
may give some indication as to whether alteration of VE
with CKD status is likely. A large observational study of
pneumococcal vaccine found no evidence of effective-
ness against hospitalization for pneumonia or respiratory
infections among patients receiving dialysis.39 A study of
inﬂuenza vaccine which calculated a ratio-of-ratios VE
comparing inﬂuenza effectiveness in years with good
match between the vaccine and circulating strain to
effectiveness in a poorly matched ‘placebo year’ found
no evidence of protection against inﬂuenza/pneumonia
hospitalization among patients receiving hemodialysis
(VE 2%: 95% CI −2% to5%).20 These studies suggest
that the suggestion of reduced pneumococcal VE asso-
ciated with CKD is plausible, but this question requires
further investigation before conclusions can be drawn.
This study has several strengths. We used large, linked
data sets with a careful deﬁnition of infection episodes
to identify community-acquired infections managed in
primary or secondary care, and excluded hospital-
acquired infections and hospitalization from time at risk.
This avoids differential hospital attendance patterns
biasing estimates of VE according to markers of CKD.
We adjusted for a wide range of comorbidities, and con-
ducted a ratio-of-ratios analysis for inﬂuenza VE to
address confounding by indication. We described the
effect of pneumococcal vaccine according to time since
vaccination, including booster doses, to identify waning
immunity following vaccination. Our study population of
older people with diabetes is well monitored for CKD,40
and this permitted us to explore the relationship of
inﬂuenza and pneumococcal VE with CKD among
patients not receiving dialysis, which we believe is novel.
As an observational study of VE using routinely collected
health record data, the study has limitations. LRTI/pneu-
monia is typically diagnosed clinically in general practice,
without microbiological testing for the causative pathogen.
Thus, we chose broader LRTI/pneumonia outcomes, in
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common with previous observational studies of inﬂuenza
VE. We may have underascertained proteinuria and
comorbidities; however, the selection of a highly monitored
study population should minimize this risk, and the high
prevalence of each we observed suggests that this was not a
major source of misclassiﬁcation. Despite adjustment for
multiple comorbidities, residual confounding by indication
may remain in the pneumococcal VE analysis. Despite our
use of large, linked data sets, we had limited power to esti-
mate the relationship of VE according to CKD status, espe-
cially in a ratio-of-ratios inﬂuenza VE analysis.
Our ﬁndings have implications for clinical practice,
public health, and future research. Our results should
not be interpreted as demonstrating that inﬂuenza
vaccine is ineffective among this population. We did not
study the effectiveness of either vaccine against infection
with their speciﬁc pathogens. As such, the results should
neither discourage patients nor health professionals
from inﬂuenza and pneumococcal vaccination.
Our study question was the extent to which the
burden of community-acquired LRTI may be prevent-
able with vaccination and our results suggest that the
growing burden of community-acquired LRTI and pneu-
monia among this population cannot be easily tackled
by increasing uptake of existing routine vaccination pro-
grams. This is relevant for public health—in planning
health service provision and designing effective strat-
egies to prevent illness. It should also prompt a call for
research into more effective immunization strategies and
vaccination schedules. The low inﬂuenza VE we
observed against community-acquired LRTI, when con-
trasted with the large burden of infection directly and
indirectly attributed to inﬂuenza, suggests scope for
strategies to improve vaccination effectiveness and better
immunization among this population, for example, the
use of adjuvants in vaccines. The suggestion of reduced
pneumococcal VE among patients with proteinuria is
interesting and needs conﬁrmation in a repeat study.
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